Free Trial

MetLife (MET) Stock Price, News & Analysis

$72.81
+0.09 (+0.12%)
(As of 08/21/2024 ET)
Today's Range
$72.41
$73.06
50-Day Range
$67.96
$76.85
52-Week Range
$57.91
$79.34
Volume
2.01 million shs
Average Volume
3.37 million shs
Market Capitalization
$51.78 billion
P/E Ratio
25.02
Dividend Yield
2.99%
Price Target
$83.00

MetLife MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.92 Rating Score
Upside/​Downside
14.0% Upside
$83.00 Price Target
Short Interest
Healthy
1.36% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
0.45mentions of MetLife in the last 14 days
Based on 14 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
13.34%
From $8.62 to $9.77 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.96 out of 5 stars

Finance Sector

11th out of 863 stocks

Life Insurance Industry

3rd out of 20 stocks

MET stock logo

About MetLife Stock (NYSE:MET)

MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives. In addition, it provides fixed, indexed-linked, and variable annuities; pension products; regular savings products; whole and term life, endowments, universal and variable life, and group life products; longevity reinsurance solutions; credit insurance products; and protection against long-term health care services. MetLife, Inc. was incorporated in 1999 and is based in New York, New York.

MET Stock Price History

MET Stock News Headlines

Morgan Stanley Lowers MetLife (NYSE:MET) Price Target to $85.00
US developing “superweapon” to defeat China and Russia?
Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will create the greatest investment opportunity for Americans since WWII. Similar stocks in the past have seen peak gains of 16,270%in just 18 months.
Morgan Stanley Sticks to Its Buy Rating for Metlife (MET)
MetLife Investment Management Names Jude Driscoll President
US developing “superweapon” to defeat China and Russia?
Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will create the greatest investment opportunity for Americans since WWII. Similar stocks in the past have seen peak gains of 16,270%in just 18 months.
See More Headlines
Receive MET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MetLife and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 6/11 Dividend
5/06/2024
Dividend Payable
6/11/2024
Last Earnings
7/31/2024
Ex-Dividend for 9/10 Dividend
8/06/2024
Today
8/21/2024
Dividend Payable
9/10/2024
Next Earnings (Estimated)
11/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Finance
Industry
Life insurance
Sub-Industry
Life & Health Insurance
CUSIP
59156R10
Employees
45,000
Year Founded
1868

Price Target and Rating

Average Stock Price Target
$83.00
High Stock Price Target
$96.00
Low Stock Price Target
$71.00
Potential Upside/Downside
+14.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
13 Analysts

Profitability

Net Income
$1.58 billion
Pretax Margin
5.41%

Debt

Sales & Book Value

Annual Sales
$67.95 billion
Cash Flow
$6.45 per share
Book Value
$38.73 per share

Miscellaneous

Free Float
708,919,000
Market Cap
$51.78 billion
Optionable
Optionable
Beta
1.11

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Should I Buy MetLife Stock? MET Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in MetLife, Inc.:

  • MetLife's recent earnings report exceeded analysts' expectations, with earnings per share of $2.28 for the quarter, beating estimates by $0.15. This indicates strong financial performance.
  • MetLife's dividend payout ratio is currently 74.91%, offering investors a solid dividend yield of 3.13%. This can provide a steady income stream.
  • Analysts have given MetLife a consensus rating of "Moderate Buy" with an average price target of $82.85, suggesting potential for stock price appreciation.
  • MetLife has initiated a share repurchase plan, indicating confidence in the company's value and potentially boosting shareholder returns.
  • MetLife's diverse range of financial services, including insurance, annuities, employee benefits, and asset management, provides a well-rounded investment opportunity in the financial sector.

Cons

Investors should be bearish about investing in MetLife, Inc. for these reasons:

  • MetLife's current ratio and quick ratio are both low at 0.16, indicating potential liquidity challenges and a higher risk profile for investors.
  • MetLife's stock price has been fluctuating, trading down to $69.85 recently. This volatility may pose a risk for short-term investors.
  • While MetLife's return on equity is strong at 21.41%, the company's debt-to-equity ratio of 0.56 suggests a moderate level of debt that could impact financial stability.
  • Market analysts have issued mixed ratings on MetLife, with one hold rating alongside multiple buy ratings. This divergence in opinions may lead to uncertainty in the stock's performance.
  • MetLife's revenue in the recent quarter was slightly below analyst estimates, which could indicate challenges in revenue growth and market competitiveness.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, August 15, 2024. Please send any questions or comments about these MetLife pros and cons to contact@marketbeat.com.

MET Stock Analysis - Frequently Asked Questions

How have MET shares performed this year?

MetLife's stock was trading at $66.13 at the beginning of the year. Since then, MET shares have increased by 10.1% and is now trading at $72.81.
View the best growth stocks for 2024 here
.

How were MetLife's earnings last quarter?

MetLife, Inc. (NYSE:MET) released its quarterly earnings data on Wednesday, July, 31st. The financial services provider reported $2.28 EPS for the quarter, topping analysts' consensus estimates of $2.13 by $0.15. The company's quarterly revenue was up 7.2% on a year-over-year basis.
Read the conference call transcript
.

Is MetLife doing a stock buyback?

MetLife's board authorized a stock buyback program on Wednesday, May 1st 2024, which permits the company to buy back $3,000,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 6% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's management believes its stock is undervalued.

What is Michel Khalaf's approval rating as MetLife's CEO?

308 employees have rated MetLife Chief Executive Officer Michel Khalaf on Glassdoor.com. Michel Khalaf has an approval rating of 89% among the company's employees.

Does MetLife have any subsidiaries?

MetLife subsidiaries include Versant Health, Willing, Logan Circle Partners, American Life Insurance Company, Safeguard Health Enterprises, Grand Bank N.A., General American Life Insurance Company, and others.

Who are MetLife's major shareholders?

Top institutional shareholders of MetLife include Pzena Investment Management LLC (1.36%), Dimensional Fund Advisors LP (0.76%), Legal & General Group Plc (0.75%) and Bank of New York Mellon Corp (0.61%). Insiders that own company stock include Steven J Goulart, Ramy Tadros, Marlene Debel, Bill Pappas, Susan M Podlogar, Jeh C Johnson and Michel Khalaf.
View institutional ownership trends
.

How do I buy shares of MetLife?

Shares of MET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of MetLife own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MetLife investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), General Electric (GE), International Business Machines (IBM), Exxon Mobil (XOM) and Intel (INTC).

This page (NYSE:MET) was last updated on 8/22/2024 by MarketBeat.com Staff

From Our Partners